Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study

scientific article

Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1023913531
P356DOI10.1186/S12902-016-0101-2
P932PMC publication ID4890276
P698PubMed publication ID27255309

P50authorRobert Alan GreevyQ89613050
Marie R. GriffinQ89613053
Christianne L. RoumieQ89613055
Carlos G. GrijalvaQ89613057
P2093author name stringAdriana M Hung
Xulei Liu
P2860cites workComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsQ22241134
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Q22241288
Patient perceptions of quality of life with diabetes-related complications and treatmentsQ24644699
Diabetes in older adultsQ30528669
Estimating medication persistency using administrative claims data.Q30996673
Service utilization of veterans dually eligible for VA and Medicare fee-for-service: 1999-2004.Q33551536
Treatment intensification and risk factor control: toward more clinically relevant quality measuresQ33988413
Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpilingQ34065562
Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetesQ34109319
Drug titration patterns and HbA 1c levels in type 2 diabetesQ34322132
Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalizationQ34573073
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort studyQ34644993
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.Q34988073
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implicationsQ35141566
Comparative effectiveness of incident oral antidiabetic drugs on kidney functionQ35835288
Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD studyQ35864363
Standards of medical care in diabetes--2009.Q37036416
Medication compliance and persistence: terminology and definitionsQ37072950
Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trialsQ37866586
Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.Q38001085
The other side of quality improvement in diabetes for seniors: a proposal for an overtreatment glycemic measureQ38042350
Veterans' access to and use of Medicare and Veterans Affairs health careQ38463957
Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.Q44453230
Changing incident diabetes regimens: a Veterans Administration cohort study from 2000 to 2005.Q45332206
Evaluating Medication Effects Outside of Clinical Trials: New-User DesignsQ52956338
Executive summary: standards of medical care in diabetes--2009Q56481478
P433issue1
P304page(s)32
P577publication date2016-06-02
P1433published inBMC Endocrine DisordersQ4835945
P1476titleDiabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study
P478volume16

Reverse relations

cites work (P2860)
Q49967667Association Between Metformin Adherence and All-Cause Mortality Among New Users of Metformin: A Nested Case-Control Study
Q90177360Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function
Q46441179Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
Q38829782Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
Q92544171Dose distribution and up-titration patterns of metformin monotherapy in patients with type 2 diabetes
Q43540210Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.
Q28078294The neurobiology of the Prader-Willi phenotype of fragile X syndrome

Search more.